.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,377,921

« Back to Dashboard

Claims for Patent: 8,377,921

Title:Compounds and compositions as protein kinase inhibitors
Abstract: The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.
Inventor(s): Michellys; Pierre-Yves (San Marcos, CA), Pei; Wei (San Diego, CA), Marsilje; Thomas H. (San Diego, CA), Chen; Bei (San Diego, CA), Uno; Tetsuo (San Diego, CA)
Assignee: IRM LLC (Hamilton, BM)
Application Number:13/172,572
Patent Claims: 1. A method for treating a condition mediated by anaplastic lymphoma kinase, comprising administering to a subject in need of treatment, a therapeutically effective amount of a compound of Formula (2), ##STR00361## or pharmaceutically acceptable salts thereof; wherein R.sup.1 is halo or C.sub.1-6 alkyl; R.sup.2 is H; R.sup.3 is (CR.sub.2).sub.0-2SO.sub.2R.sup.12; R.sup.4 is C.sub.1-6 alkyl, C.sub.2-6 alkenyl or C.sub.2-6 alkynyl; OR.sup.12, NR(R.sup.12), halo, nitro, SO.sub.2R.sup.12, (CR.sub.2).sub.pR.sup.13 or X; or R.sup.4 is H; R.sup.6 is isopropoxy or methoxy; one of R.sup.8 and R.sup.9 is (CR.sub.2).sub.qY and the other is C.sub.1-6 alkyl, cyano, C(O)O.sub.0-1R.sup.12, CONR(R.sup.12) or CONR(CR.sub.2).sub.pNR(R.sup.12); X is (CR.sub.2).sub.qY, cyano, C(O)O.sub.0-1R.sup.12, CONR(R.sup.12), CONR(CR.sub.2).sub.pNR(R.sup.12), CONR(CR.sub.2).sub.pOR.sup.12, CONR(CR.sub.2).sub.pSR.sup.12, CONR(CR.sub.2).sub.pS(O).sub.1-2R.sup.12 or (CR.sub.2).sub.1-6NR(CR.sub.2).sub.pOR.sup.12; Y is pyrrolidinyl, piperidinyl or azetidinyl, each of which is attached to the phenyl ring via a carbon atom; R.sup.12 and R.sup.13 are independently 3-7 membered saturated or partially unsaturated carbocyclic ring, or a 5-7 membered heterocyclic ring comprising N, O and/or S; aryl or heteroaryl; or R.sup.12 is H or C.sub.1-6 alkyl; R is H or C.sub.1-6 alkyl; n is 0-1; p is 0-4; and q is 0; and optionally in combination with a second therapeutic agent, wherein said condition is anaplastic large cell lymphoma, ALK+ non-Hodgkin's lymphoma, inflammatory myofibrolastic tumor, neuroblastoma or a neoplastic disease, wherein said neoplastic disease is non-small cell lung cancer.

2. The method of claim 1, wherein said condition is non-small cell lung cancer.

3. The method of claim 1, wherein said condition is neuroblastoma.

4. The method of claim 1, wherein said second therapeutic agent is a chemotherapeutic agent.

5. A method for treating a condition mediated by anaplastic lymphoma kinase, comprising administering to a subject in need of treatment, a therapeutically effective amount of a compound of Formula (1) ##STR00362## or pharmaceutically acceptable salts thereof; wherein W is ##STR00363## A.sup.1 and A.sup.4 are independently C; each A.sup.2 and A.sup.3 is C; R.sup.1 is halo or C.sub.1-6 alkyl; R.sup.2 is H; R.sup.3 is (CR.sub.2).sub.0-2SO.sub.2R.sup.12; R.sup.4 is H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl or C.sub.2-6 alkynyl; OR.sup.12, NR(R.sup.12), halo, nitro, SO.sub.2R.sup.12, (CR.sub.2).sub.pR.sup.13 or X; R.sup.5, R.sup.5', R.sup.7 and R.sup.10 are H; R.sup.6 is C.sub.1-6 alkyl, C.sub.2-6 alkenyl or C.sub.2-6 alkynyl; OR.sup.12, NR(R.sup.12), halo, nitro, SO.sub.2R.sup.12, (CR.sub.2).sub.pR.sup.13 or X; R.sup.8 and R.sup.9 are independently C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, halo or X; and provided one of R.sup.8 and R.sup.9 is X; R is H or C.sub.1-6 alkyl; X is (CR.sub.2).sub.qY; Y is a 5-12 membered heterocyclic ring comprising N, O and/or S, and optionally substituted with C.sub.1-6 alkyl, hydroxylC.sub.1-C.sub.8alkyl, C.sub.1-C.sub.8alkoxyC.sub.1-C.sub.8alkyl or a 5-12 membered heterocyclic ring comprising N, O and/or S; and wherein Y is attached to A.sup.2 or A.sup.3 or both via a carbon atom of said heterocyclic ring when q in (CR.sub.2).sub.qY is 0; R.sup.12 and R.sup.13 are independently 3-7 membered saturated or partially unsaturated carbocyclic ring, or a 5-7 membered heterocyclic ring comprising N, O and/or S; aryl or heteroaryl; or R.sup.12 is H, C.sub.1-6 alkyl; p is 0-4; and n and q are 0; and optionally in combination with a second therapeutic agent, wherein said condition is anaplastic large cell lymphoma, ALK+ non-Hodgkin's lymphoma, inflammatory myofibrolastic tumor, neuroblastoma or a neoplastic disease, wherein said neoplastic disease is non-small cell lung cancer.

6. The method of claim 1, wherein said compound is selected from the group consisting of: ##STR00364## ##STR00365## or pharmaceutically acceptable salts thereof.

7. The method of claim 1, wherein said compound is 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propa- ne-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine, or a pharmaceutically acceptable salt thereof.

8. The method of claim 5, wherein said compound is selected from the group consisting of ##STR00366## ##STR00367## ##STR00368## or pharmaceutically acceptable salts thereof.

9. The method of claim 5, wherein said compound is N2-(2-isopropoxy-5-methyl-4-(1-methylpiperidin-4-yl)phenyl)-N4-(2-(isopro- pylsulfonyl)phenyl)-5-methylpyrimidine-2,4-diamine.

10. A method for treating a condition which responds to inhibition of anaplastic lymphoma kinase, comprising administering a therapeutically effective amount of a compound of Formula (2), ##STR00369## wherein R.sup.1 is halo or C.sub.1-6 alkyl; R.sup.2 is H; R.sup.3 is (CR.sub.2).sub.0-2SO.sub.2R.sup.12; R.sup.4 is C.sub.1-6 alkyl, C.sub.2-6 alkenyl or C.sub.2-6 alkynyl; OR.sup.12, NR(R.sup.12), halo, nitro, SO.sub.2R.sup.12, (CR.sub.2).sub.pR.sup.13 or X; or R.sup.4 is H; R.sup.6 is isopropoxy or methoxy; one of R.sup.8 and R.sup.9 is (CR.sub.2).sub.qY and the other is C.sub.1-6 alkyl, cyano, C(O)O.sub.0-1R.sup.12, CONR(R.sup.12) or CONR(CR.sub.2).sub.pNR(R.sup.12); X is (CR.sub.2).sub.qY, cyano, C(O)O.sub.0-1R.sup.12, CONR(R.sup.12), CONR(CR.sub.2).sub.pNR(R.sup.12), CONR(CR.sub.2).sub.pOR.sup.12, CONR(CR.sub.2).sub.pSR.sup.12, CONR(CR.sub.2).sub.pS(O).sub.1-2R.sup.12 or (CR.sub.2).sub.1-6NR(CR.sub.2).sub.pOR.sup.12; Y is pyrrolidinyl, piperidinyl or azetidinyl, each of which is attached to the phenyl ring via a carbon atom; R.sup.12 and R.sup.13 are independently 3-7 membered saturated or partially unsaturated carbocyclic ring, or a 5-7 membered heterocyclic ring comprising N, O and/or S; aryl or heteroaryl; or R.sup.12 is H or C.sub.1-6 alkyl; R is H or C.sub.1-6 alkyl; n is 0-1; p is 0-4; and q is 0; or a pharmaceutically acceptable salts thereof, and optionally in combination with a second therapeutic agent, to a subject in need of treatment; wherein said condition is anaplastic large cell lymphoma, ALK+ non-Hodgkin's lymphoma, inflammatory myofibrolastic tumor, neuroblastoma or a neoplastic disease, wherein said neoplastic disease is non-small cell lung cancer.

11. The method of claim 10, wherein said condition is non-small cell lung cancer.

12. The method of claim 10, wherein said condition is neuroblastoma.

13. The method of claim 10, wherein said second therapeutic agent is a chemotherapeutic agent.

14. The method of claim 10, wherein said compound is selected from the group consisting of: ##STR00370## ##STR00371## or pharmaceutically acceptable salts thereof.

15. The method of claim 10, wherein said compound is 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propa- ne-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine, or a pharmaceutically acceptable salt thereof.

16. A method for treating a condition which responds to inhibition of anaplastic lymphoma kinase, comprising administering a therapeutically effective amount of a compound of Formula (1), ##STR00372## wherein W is ##STR00373## A.sup.1 and A.sup.4 are independently C; each A.sup.2 and A.sup.3 is C; R.sup.1 is halo or C.sub.1-6 alkyl; R.sup.2 is H; R.sup.3 is (CR.sub.2).sub.0-2SO.sub.2R.sup.12; R.sup.4 is H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl or C.sub.2-6 alkynyl; OR.sup.12, NR(R.sup.12), halo, nitro, SO.sub.2R.sup.12, (CR.sub.2).sub.pR.sup.13 or X; R.sup.5, R.sup.5', R.sup.7 and R.sup.10 are H; R.sup.6 is C.sub.1-6 alkyl, C.sub.2-6 alkenyl or C.sub.2-6 alkynyl; OR.sup.12, NR(R.sup.12), halo, nitro, SO.sub.2R.sup.12, (CR.sub.2).sub.pR.sup.13 or X; R.sup.8 and R.sup.9 are independently C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, halo or X; and provided one of R.sup.8 and R.sup.9 is X; R is H or C.sub.1-6 alkyl; X is (CR.sub.2).sub.qY; Y is a 5-12 membered heterocyclic ring comprising N, O and/or S, and optionally substituted with C.sub.1-6 alkyl, hydroxylC.sub.1-C.sub.8alkyl, C.sub.1-C.sub.8alkoxyC.sub.1-C.sub.8alkyl or a 5-12 membered heterocyclic ring comprising N, O and/or S; and wherein Y is attached to A.sup.2 or A.sup.3 or both via a carbon atom of said heterocyclic ring when q in (CR.sub.2).sub.qY is 0; R.sup.12 and R.sup.13 are independently 3-7 membered saturated or partially unsaturated carbocyclic ring, or a 5-7 membered heterocyclic ring comprising N, O and/or S; aryl or heteroaryl; or R.sup.12 is H, C.sub.1-6 alkyl; p is 0-4; and n and q are 0; or a pharmaceutically acceptable salt thereof, and optionally in combination with a second therapeutic agent, to a subject in need of treatment; wherein said condition is anaplastic large cell lymphoma, ALK+ non-Hodgkin's lymphoma, inflammatory myofibrolastic tumor, non-small cell lung cancer or neuroblastoma.

17. The method of claim 16, wherein said condition is non-small cell lung cancer.

18. The method of claim 16, wherein said condition is neuroblastoma.

19. The method of claim 16, wherein said compound is selected from the group consisting of ##STR00374## ##STR00375## ##STR00376## or pharmaceutically acceptable salts thereof.

20. The method of claim 16, wherein said compound is N2-(2-isopropoxy-5-methyl-4-(1-methylpiperidin-4-yl)phenyl)-N4-(2-(isopro- pylsulfonyl)phenyl)-5-methylpyrimidine-2,4-diamine.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc